Affordable Access

deepdyve-link
Publisher Website

Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial.

Authors
  • Neal, Bruce1, 2, 3, 4
  • Perkovic, Vlado1, 5
  • Matthews, David R6
  • Mahaffey, Kenneth W7
  • Fulcher, Greg5
  • Meininger, Gary8
  • Erondu, Ngozi8
  • Desai, Mehul8
  • Shaw, Wayne8
  • Vercruysse, Frank9
  • Yee, Jacqueline8
  • Deng, Hsiaowei8
  • de Zeeuw, Dick10
  • 1 The George Institute for Global Health, Sydney, Australia. , (Australia)
  • 2 The Charles Perkins Centre, University of Sydney, Sydney, Australia. , (Australia)
  • 3 Royal Prince Alfred Hospital, Sydney, Australia. , (Australia)
  • 4 Imperial College London, London, UK.
  • 5 The Royal North Shore Hospital, University of Sydney, Sydney, Australia. , (Australia)
  • 6 University of Oxford, Oxford, UK.
  • 7 Department of Medicine, Stanford Center for Clinical Research (SCCR), Stanford University, Stanford, California.
  • 8 Janssen Research & Development, LLC, Raritan, New Jersey. , (Jersey)
  • 9 Janssen Research & Development, Beerse, Belgium. , (Belgium)
  • 10 University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. , (Netherlands)
Type
Published Article
Journal
Diabetes, obesity & metabolism
Publication Date
Mar 01, 2017
Volume
19
Issue
3
Pages
387–393
Identifiers
DOI: 10.1111/dom.12829
PMID: 28120497
Source
Medline
Keywords
License
Unknown

Abstract

The trial should define the potential renoprotective effect of canagliflozin and will provide additional important new data about its effects on vascular outcomes, death and kidney failure.

Report this publication

Statistics

Seen <100 times